{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:49:16Z","timestamp":1783032556759,"version":"3.54.6"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,21]],"date-time":"2014-05-21T00:00:00Z","timestamp":1400630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.jval.2014.01.007","type":"journal-article","created":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T05:16:34Z","timestamp":1403500594000},"page":"320-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Long-Term Air Humidification Therapy Is Cost-Effective for Patients with Moderate or Severe Chronic Obstructive Pulmonary Disease or Bronchiectasis"],"prefix":"10.1016","volume":"17","author":[{"given":"Richard J.","family":"Milne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hockey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2014.01.007_bib1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2011. Available from: http:\/\/www.goldcopd.org. [Accessed April 11, 2014]."},{"key":"10.1016\/j.jval.2014.01.007_bib2","unstructured":"World Health Organization. Chronic obstructive pulmonary disease (COPD). 2004. Available from: www.who.int\/respiratory\/copd\/en\/index.html. [Accessed March 31, 2014]."},{"key":"10.1016\/j.jval.2014.01.007_bib3","first-page":"71","article-title":"Pharmacoeconomics in COPD: lessons for the future","volume":"3","author":"Starkie","year":"2008","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.jval.2014.01.007_bib4","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thx.2010.136119","article-title":"British Thoracic Society guideline for non-CF bronchiectasis","volume":"65","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jval.2014.01.007_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1440-1843.2005.00692.x","article-title":"Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective","volume":"10","year":"2005","journal-title":"Respirology"},{"key":"10.1016\/j.jval.2014.01.007_bib6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1183\/09031936.00157906","article-title":"COPD prevalence in a random population survey: a matter of definition","volume":"30","author":"Shirtcliffe","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jval.2014.01.007_bib7","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1111\/j.1445-5994.2011.02444.x","article-title":"Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis","volume":"42","author":"Roberts","year":"2012","journal-title":"Intern Med J"},{"key":"10.1016\/j.jval.2014.01.007_bib8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00008483-200207000-00004","article-title":"Global initiative for chronic obstructive lung disease","volume":"22","author":"Gerald","year":"2002","journal-title":"J Cardiopulm Rehabil"},{"issue":"Suppl.","key":"10.1016\/j.jval.2014.01.007_bib9","first-page":"S7","article-title":"The COPDX Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2003","volume":"178","author":"McKenzie","year":"2003","journal-title":"Med J Aust"},{"issue":"Suppl. B","key":"10.1016\/j.jval.2014.01.007_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0954-6111(06)80166-6","article-title":"The St George\u2019s Respiratory Questionnaire","volume":"85","author":"Jones","year":"1991","journal-title":"Respir Med"},{"issue":"2, Pt 1","key":"10.1016\/j.jval.2014.01.007_bib11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1164\/ajrccm.156.2.9607083","article-title":"Validation of the St. George\u2019s Respiratory Questionnaire in bronchiectasis","volume":"156","author":"Wilson","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jval.2014.01.007_bib12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.rmed.2009.12.016","article-title":"The clinical utility of long-term humidification therapy in chronic airway disease","volume":"104","author":"Rea","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.jval.2014.01.007_bib13","first-page":"81","article-title":"Domiciliary humidification improves lung mucociliary clearance in patients with bronchiectasis","volume":"5","author":"Hasani","year":"2008","journal-title":"Chron"},{"key":"10.1016\/j.jval.2014.01.007_bib14","series-title":"Prescription for Pharmacoeconomic Analysis, Version 2.1","year":"2012"},{"key":"10.1016\/j.jval.2014.01.007_bib15","unstructured":"Drummond M, O\u2019Brien B, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes (2nd ed.). New York, NY: Oxford Medical Publications, 1997."},{"key":"10.1016\/j.jval.2014.01.007_bib16","doi-asserted-by":"crossref","unstructured":"Metcalfe S, Grocott R. Comments on \u201cSimoens, S. Health economic assessment: a methodological primer.\u201d Int J Environ Res Public Health 2010;7:1831\u20134.","DOI":"10.3390\/ijerph7041831"},{"key":"10.1016\/j.jval.2014.01.007_bib17","unstructured":"PHARMAC. New Zealand pharmaceutical schedule. 2012. Available from: http:\/\/www.pharmac.govt.nz\/Schedule. [Accessed March 31, 2014]."},{"key":"10.1016\/j.jval.2014.01.007_bib18","unstructured":"PHARMAC. Resource manual. 2012. Available from: http:\/\/www.pharmac.govt.nz\/?q=resource+manual. [Accessed March 31, 2014]."},{"key":"10.1016\/j.jval.2014.01.007_bib19","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jval.2010.09.011","article-title":"Predicting EQ-5D values using the SGRQ","volume":"14","author":"Starkie","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2014.01.007_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00019053-199915020-00003","article-title":"Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II","volume":"15","author":"Samsa","year":"1999","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2014.01.007_bib21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.0.CO;2-O","article-title":"Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane","volume":"7","author":"Briggs","year":"1998","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2014.01.007_bib22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/hec.1477","article-title":"Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared","volume":"19","author":"Nixon","year":"2010","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2014.01.007_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40273-012-0011-8","article-title":"Cost-effectiveness acceptability curves revisited","volume":"31","author":"Al","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2014.01.007_bib24","unstructured":"MRC. Bootstrap spreadsheet. 2005. Available from: http:\/\/mrcblogs.helpfulclients.com\/bsu\/software\/software-downloads\/. [Accessed March 31, 2014]."},{"key":"10.1016\/j.jval.2014.01.007_bib25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1378\/chest.09-2029","article-title":"Increased risk of myocardial infarction and stroke following exacerbation of COPD","volume":"137","author":"Donaldson","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jval.2014.01.007_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1465-9921-12-7","article-title":"Determinants of elevated healthcare utilization in patients with COPD","volume":"12","author":"Simon-Tuval","year":"2011","journal-title":"Respir Res"},{"key":"10.1016\/j.jval.2014.01.007_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/COPD.S13771","article-title":"Direct costs of chronic obstructive pulmonary disease among managed care patients","volume":"5","author":"Dalal","year":"2010","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.jval.2014.01.007_bib28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/11535600-000000000-00000","article-title":"A new method for examining the cost savings of reducing COPD exacerbations","volume":"28","author":"Mapel","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2014.01.007_bib29","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.rmed.2006.03.011","article-title":"Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore","volume":"100","author":"Lee","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.jval.2014.01.007_bib30","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.rmed.2009.02.002","article-title":"Impact of hospitalisations for exacerbations of COPD on health-related quality of life","volume":"103","author":"Esteban","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.jval.2014.01.007_bib31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1183\/09031936.02.00238702","article-title":"Improved health outcomes in patients with COPD during 1 yr\u2019s treatment with tiotropium","volume":"19","author":"Vincken","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jval.2014.01.007_bib32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [Reprint in Ugeskr Laeger 2007;169:3198\u2013201]","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2014.01.007_bib33","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1378\/chest.128.2.739","article-title":"Quality-of-life determinants in patients with clinically stable bronchiectasis","volume":"128","author":"Martinez-Garcia","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jval.2014.01.007_bib34","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2014.01.007_bib35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1183\/09031936.00082909","article-title":"Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial [Erratum appears in Eur Respir J 2010;35:1195]","volume":"35","author":"Tashkin","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jval.2014.01.007_bib36","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.rmed.2008.06.016","article-title":"EuroQoL in assessment of the effect of pulmonary rehabilitation COPD patients","volume":"102","author":"Ringbaek","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.jval.2014.01.007_bib37","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/15412555.2011.630248","article-title":"A comparison of the assessment of quality of life with CAT, CCQ, and SGRQ in COPD patients participating in pulmonary rehabilitation","volume":"9","author":"Ringbaek","year":"2012","journal-title":"COPD"},{"key":"10.1016\/j.jval.2014.01.007_bib38","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1378\/chest.130.4.1117","article-title":"Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?","volume":"130","author":"MPMH","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.jval.2014.01.007_bib39","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.rmed.2012.09.006","article-title":"Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium","volume":"106","author":"Hettle","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.jval.2014.01.007_bib40","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/hec.741","article-title":"Logical inconsistencies in survey respondents\u2019 health state valuations \u2013 a methodological challenge for estimating social tariffs","volume":"12","author":"Devlin","year":"2003","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2014.01.007_bib41","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2165\/11589280-000000000-00000","article-title":"Utility estimation in chronic obstructive pulmonary disease: a preference for change?","volume":"29","author":"Petrillo","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2014.01.007_bib42","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1183\/09031936.00153108","article-title":"Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study","volume":"35","author":"Briggs","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jval.2014.01.007_bib43","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s11136-004-7713-0","article-title":"Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D","volume":"14","author":"Walters","year":"2005","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2014.01.007_bib44","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2147\/COPD.S29820","article-title":"Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis","volume":"7","author":"Hertel","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.jval.2014.01.007_bib45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/11589270-000000000-00000","article-title":"Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues","volume":"30","author":"Rutten-van Molken","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2014.01.007_bib46","unstructured":"PHARMAC. Decision criteria. 2011. Available from: http:\/\/www.pharmac.govt.nz\/suppliers\/DecisionMakingProcess\/DecisionCriteria. [Accessed March 31, 2014]."},{"key":"10.1016\/j.jval.2014.01.007_bib47","first-page":"99","article-title":"PHARMAC has no cost-effectiveness threshold","volume":"125","author":"Metcalfe","year":"2012","journal-title":"N Z Med J"},{"key":"10.1016\/j.jval.2014.01.007_bib48","unstructured":"Organisation for Economic Co-operation and Development. Purchasing power parity. 2012. Available from: http:\/\/stats.oecd.org\/Index.aspx?datasetcode=SNA_TABLE4. [Accessed March 31, 2014]."},{"key":"10.1016\/j.jval.2014.01.007_bib49","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/hec.864","article-title":"Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis","volume":"13","author":"Devlin","year":"2004","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2014.01.007_bib50","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1258\/jhsrp.2012.011098","article-title":"Is the aim of the English health care system to maximize QALYs?","volume":"17","author":"Shah","year":"2012","journal-title":"J Health Serv Res Policy"},{"key":"10.1016\/j.jval.2014.01.007_bib51","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","article-title":"The NICE cost-effectiveness threshold: what it is and what that means","volume":"26","author":"McCabe","year":"2008","journal-title":"Pharmacoeconomics"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301514000151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301514000151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T05:26:57Z","timestamp":1538544417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301514000151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1098301514000151"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2014.01.007","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Air Humidification Therapy Is Cost-Effective for Patients with Moderate or Severe Chronic Obstructive Pulmonary Disease or Bronchiectasis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2014.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}